Last reviewed · How we verify
Lynparza
At a glance
| Generic name | Lynparza |
|---|---|
| Also known as | Olaparib |
| Sponsor | University of Texas Southwestern Medical Center |
| Target | Mono [ADP-ribose] polymerase PARP16, Tankyrase-1, Tankyrase-2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- BRCA mutation-positive and HER2-negative breast cancer
- Epithelial tumor of ovary
- Hormone refractory prostate cancer
- Human epidermal growth factor 2 negative carcinoma of breast
- Malignant tumor of ovary
- Malignant tumor of pancreas
- Malignant tumor of peritoneum
Common side effects
- Nausea
- Fatigue
- Vomiting
- Abdominal pain
- Diarrhea
- Anemia
- Constipation
- Upper respiratory tract infection/influenza/nasopharyngitis/bronchitis
- Dyspepsia
- Neutropenia
- Leukopenia
- Thrombocytopenia
Serious adverse events
- Anemia
- Diarrhea
- Abdominal pain
- Fatigue
- Neutropenia
- Leukopenia
- Thrombocytopenia
- Nausea
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer (PHASE2)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (PHASE2)
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |